ESTA240920P42500
- 2.48
- -0.27-9.82%
Establishment Labs Newsroom
Establishment Labs Hldgs Analyst Ratings
Citi Maintains Establishment Labs(ESTA.US) With Hold Rating, Cuts Target Price to $45
Establishment Labs Holdings: A Cautious Hold Amid FDA Approval Process and High Short Interest
Establishment Labs Price Target Maintained With a $68.00/Share by Stephens & Co.
Establishment Labs Hldgs Analyst Ratings
JP Morgan Maintains Overweight on Establishment Labs Hldgs, Lowers Price Target to $50
Establishment Labs Holdings Poised for U.S. Market Entry: A Buy Rating Analysis
TD Cowen Maintains Establishment Labs(ESTA.US) With Buy Rating, Maintains Target Price $75
Citigroup Maintains Neutral on Establishment Labs Hldgs, Lowers Price Target to $50
Establishment Labs Hldgs Analyst Ratings
Establishment Labs Hldgs Analyst Ratings
Mizuho Maintains Buy on Establishment Labs Hldgs, Raises Price Target to $70
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Establishment Labs Hldgs Analyst Ratings
Citi: Downgraded the rating of Investing Labs Hldgs (ESTA.US) from buying to neutral, and the target price was adjusted from $60.00 to $60.00.
Citigroup Downgrades Establishment Labs Holdings to Neutral From Buy With $60 Price Target
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Cytokinetics (CYTK)
Establishment Labs Hldgs Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Gritstone Oncology (GRTS)